The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported. These molecules display enhanced nitric oxide releasing properties due to the presence of an ionisable moiety. The in vivo analgesic/anti-inflammatory activity was maintained in relation to the parent compounds. (c) 2012 Elsevier Masson SAS. All rights reserved.
Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme / Biava, M., Battilocchio, C., Poce, G., Alfonso, S., Porretta, G.C., Consalvi, S., Vincenzo, C., Alma, M., Lara, T., Carla, G., Lorenzo Di Cesare, M., Lidia, S., Antonietta, R., Antonio, G., Paola, P., Maurizio, A.. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - STAMPA. - 58:(2012), pp. 287-298. [10.1016/j.ejmech.2012.10.014]
Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme
BIAVA, Mariangela;BATTILOCCHIO, CLAUDIO;POCE, Giovanna;ALFONSO, SALVATORE;PORRETTA, Giulio Cesare;CONSALVI, SARA;
2012
Abstract
The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported. These molecules display enhanced nitric oxide releasing properties due to the presence of an ionisable moiety. The in vivo analgesic/anti-inflammatory activity was maintained in relation to the parent compounds. (c) 2012 Elsevier Masson SAS. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
